VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2020 | Efficacy of galcanezumab in older patients with migraine

Dagny Holle-Lee • 20 May 2020
EAN 2020
Headache Antibodies Galcanezumab
Prevention Treatment Trial Updates

Dagny Holle-Lee, MD, PhD, Essen University Hospital, Essen, Germany, discusses the results of three randomized, double-blind, placebo-controlled Phase III studies evaluating the early efficacy of galcanezumab in older patients with migraine. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

More from Dagny Holle-Lee

0:58
Understanding migraines better with AI
Dagny Holle-Lee • 20 May 2020
1:30
Migraine: CGRP mAbs efficacy measured over time
Dagny Holle-Lee • 20 May 2020

Related Videos

2:01
Targeting CGRP: Is it better to target the ligand or receptor in migraine prevention?
Claudia Altamura • 2 Jul 2023
2:58
Exploring the link between migraine and psychiatric comorbidities
Claudia Altamura • 2 Jul 2023
0:53
Factors influencing genetic testing for hemiplegic migraine
Irene de Boer • 1 Jul 2023
1:18
The potential of combination therapy in migraine
Alan Rapoport • 1 Jul 2023
The content of VJNeurology is intended for healthcare professionals